Try our Advanced Search for more refined results

Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals

  1. August 14, 2018

    Fed. Circ. Lets Stand Vanda Ruling That Led To USPTO Memo

    The full Federal Circuit said Tuesday it won't reconsider a panel's decision to uphold a patent for Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt, which had spurred a U.S. Patent and Trademark Office memo backing up the court on the patent eligibility of treatment methods.

  2. June 27, 2018

    Mylan Urges Full Fed. Circ. To Ax Vanda Drug IP Under Mayo

    Mylan Inc. urged the the full Federal Circuit to rehear a panel's split preservation of a patent covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt, arguing Wednesday the patent claims don't meet the U.S. Supreme Court's Mayo standard for requiring a specific method of using natural phenomena for treatment.

  3. June 14, 2018

    USPTO Memo Cuts Mayo Woes On Treatment Method Patents

    New guidance from the U.S. Patent and Trademark Office suggests that patents on methods of treating disease should usually be considered patent-eligible, freeing patent holders from having to grapple with the convoluted eligibility analysis patents must often face, attorneys say.

  4. April 13, 2018

    Vanda Schizophrenia Drug Patentable, Fed. Circ. Says

    The Federal Circuit on Friday upheld a patent covering Vanda Pharmaceuticals Inc.'s schizophrenia drug Fanapt, finding it met the U.S. Supreme Court's Mayo standard by outlining a specific method of using natural phenomena for treatment.

  5. December 05, 2017

    Roxane Fights Vanda Antipsychotic Dose Patent In Fed. Circ.

    Roxane Laboratories told a Federal Circuit panel Tuesday that Vanda Pharmaceuticals' dosage method patent for its antipsychotic Fanapt is "quintessential conventional activity," in its effort to overturn a Delaware court's finding its proposed generic version of the drug infringed the patent.